Sara Reekmans PhD
EP, BE patent attorney, Associate partner
EP, BE patent attorney, Associate partner
Biochemistry, Biotechnology, Immunology, Molecular Biology, Pharmacy
Sara is an experienced European and Belgian patent attorney with a strong scientific background and a focus on clients in the Life Sciences sector, including those active at the intersection of AI and Life Sciences. Due to the highly innovative nature of Flemish knowledge institutions and the spin-offs that result from them, Sara focuses primarily on these clients.
Before joining Arnold & Siedsma, Sara was a PhD student working on a project focused on the genetic manipulation of proteins involved in Alzheimer’s disease, with the aim of identifying a new treatment for Alzheimer’s. She then worked for a smaller patent firm for about 10 years, where she completed her training as a patent attorney.
Sara is highly skilled in the broader aspects of IP management, closely assisting her clients and taking care of everything for them, such as due diligence assignments for investments, assisting in the drafting of IP clauses in contracts, but also the day-to-day management of larger IP portfolios and coordinating these with her clients’ ongoing projects.
Detailed, structured, go-getter
*2020 – present: Owner Sunville Patents Bv and in that position she is assigned to Arnold & Siedsma as patent attorney.
2018 – 2020: Belgian and European Patent Attorney at LC Patents
2014 – 2018: European Patent Attorney at LC Patents
2009 – 2014: Trainee Patent Attorney at LC Patents
2004 – 2010: PhD – Medical Sciences at KU Leuven
2004-2010: PhD – Medical Scienceschappen (KU Leuven)
2001-2003: Master Biotechnology (UGent)
1999-2001: Bachelor Chemistry (UHasselt)
Dutch, English, German
Member of EPI
Van Gool B, Storck SE, Reekmans S, Lechat B, Gordts PLSM, Pradier L, Pietrzik CU, Roebroek AJM. “LRP1 Has a Predominant Role in Production over Clearance of Ab in a Mouse Model of Alzheimer’s Disease.” Molecular Neurobiology. 2019 Apr 19
Reekmans S., “Is there a Future for Medical/Diagnostic Patents in the US?.”- In: International Pharmaceutical Industry, Vol.5 Issue 1 (2013), p. 20-21
Roebroek AJ, Gordts PL, Reekmans S.,”Generation of a series of knock-in alleles using RMCE in ES cells”, Methods Mol Biol. 2011; 693: 277-81
Roebroek AJ, Gordts PL, Reekmans S.,”Knock-in approaches”, Methods Mol Biol. 2011; 693: 257-75
Reekmans S, Pflanzner T, Gordts PL, Isbert S, Zimmermann P, Annaert W, Weggen S, Roebroek AJ, Pietrzik CU.,”Inactivation of the proximal NPXY motif impairs early steps in LRP1 biosynthesis”, Cell Mol Life Sci. 2010 Jan; 67(1): 135-45
Gordts PL, Reekmans S, Lauwers A, Van Dongen A, Verbeek L, Roebroek AJ.,”Inactivation of the LRP1 intracellular NPxYxxL motif in LDLR-deficient mice enhances postprandial dyslipidemia and atherosclerosis”, Arterioscler Thromb Vasc Biol., 2009 Sep; 29(9): 1258-64
Roebroek AJ, Reekmans S, Lauwers A, Feyaerts N, Smeijers L, Hartmann D., “Mutant Lrp1 knock-in mice generated by recombinase-mediated cassette exchange reveal differential importance of the NPXY motifs in the intracellular domain of LRP1 for normal fetal Development”, Mol Cell Biol. 2006 Jan;26(2):605-16
